Genenta to Participate at Upcoming Investor Conferences
Genenta Science (NASDAQ: GNTA) announced its participation in several upcoming investor conferences. The events include the 34th Annual ROTH Conference on March 13-15, Maxim Group LLC 2022 Virtual Growth Conference on March 28, and the HC Wainwright Gene Therapy and Gene Editing Conference on March 30. Management, including CEO Pierluigi Paracchi and CMO Carlo Russo, will engage in fireside chats and one-on-one meetings with investors. Genenta is focused on developing Temferon™, a novel gene therapy targeting solid tumors.
- None.
- None.
MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:
34th Annual ROTH Conference, Dana Point, California, U.S.
| Date: | March 13-15, 2022 |
| Format: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
Maxim Group LLC 2022 Virtual Growth Conference
| Date: | March 28, 2022 |
| Format: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
HC Wainwright Gene Therapy and Gene Editing Conference, virtual
| Date: | March 30, 2022 |
| Presenter: | Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development |
| Management will also be available for one-on-one meetings |
8th Annual LSX World Congress, London, UK and virtual
| Date: | May 10-11, 2022 |
| Format: | Keynote panel with Pierluigi Paracchi, CEO |
| CEO will also be available for one-on-one meetings |
Further information on these events may be found on the "News & Events" section of Genenta's Investor website at https://ir.genenta.com/news-events/events.
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2 clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which should induces a durable immune response not restricted to pre-selected tumor antigens nor type and aimed at reaching solid tumors, avoid systemic toxicity, some of the main unresolved challenges in immuno-oncology.
| Investor Relations - LifeSci Advisors: | Genenta Media/Investor Contact |
| Mary-Ann Chang, CFA | Tiziana Pollio |
| +44 7483 28 48 53 | +39 3482315143 |
| mchang@lifesciadvisors.com | tiziana.pollio@genenta.com |
FAQ
What conferences will Genenta Science be attending in March 2022?
Who will represent Genenta Science at these conferences?
What is the focus of Genenta Science's Temferon™ therapy?
Is Temferon™ currently in clinical trials?
Where can I find more information about Genenta Science's upcoming events?
